Another trial studied the clinical activity of MEK1/2 inhibitors and dabrafenib combination to treat cancers especially PNFs harboring V600 mutation (Clinicaltrials.gov ID: NCT02124772). This evidence concerns the gene MAP2K1 and cancer.